SCHEMBL207273

SCHEMBL207273

CCCCCCCOc1ccc(Nc2nc(-c3ccc(-c4ccccn4)s3)cs2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.51
KMT2A Q03164 5/20 0.51
MAPT P10636 5/20 0.51
SMN1; SMN2 Q16637 4/20 0.51
PPP1CA P62136 2/20 0.51
NFKB1 P19838 2/20 0.51
NFKB2 Q00653 2/20 0.51
RELA Q04206 2/20 0.51
NR1I2 O75469 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
NR4A1 P22736 1/20 0.50
VCP P55072 1/20 0.50
NPC1 O15118 4/20 0.48
RAB9A P51151 4/20 0.48
NPY5R Q15761 1/20 0.47
CYP1A2 P05177 2/20 0.47
CYP2D6 P10635 1/20 0.47
CYP19A1 P11511 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL205471 1.00 MEN1 (0.51) MEN1KMT2AMAPTSMN1; SMN2PPP1CA
SCHEMBL206048 0.92 MAPT (0.62) MEN1KMT2AMAPTSMN1; SMN2PPP1CA
SCHEMBL205469 0.92 MAPT (0.62) MEN1KMT2AMAPTSMN1; SMN2PPP1CA
SCHEMBL206530 0.87 MAPT (0.52) MEN1KMT2AMAPTSMN1; SMN2PPP1CA
SCHEMBL206487 0.87 MAPT (0.52) MEN1KMT2AMAPTSMN1; SMN2PPP1CA
SCHEMBL208382 0.84 NPC1 (0.49) MEN1KMT2AMAPTSMN1; SMN2NFKB1
SCHEMBL206325 0.84 NPC1 (0.49) MEN1KMT2AMAPTSMN1; SMN2NFKB1
SCHEMBL204653 0.83 MEN1 (0.67) MEN1KMT2AMAPTSMN1; SMN2NFKB1
SCHEMBL206270 0.83 MEN1 (0.67) MEN1KMT2AMAPTSMN1; SMN2NFKB1
SCHEMBL207091 0.83 RAB9A (0.66) MEN1KMT2AMAPTSMN1; SMN2NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE PIGS, CPT1A, SLC10A1 MEN1 3862/4885KMT2A 3476/4885MAPT 2207/4885
US-20070004711-A1 Thiazole compounds and methods of use PIGS, CPT1A, SLC10A1 MEN1 3862/4885KMT2A 3476/4885MAPT 2207/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.